Objective: To assess tetrabenazine (TBZ) efficacy by evaluating the change in Huntington disease-associated chorea resulting from TBZ treatment withdrawal.
Methods: Thirty patients treated in the long term were randomized to 1 of 3 groups assigned to withdraw from TBZ in a double-blind, staggered fashion during a 5-day period.
Results: The chorea scores of subjects withdrawn from TBZ treatment increased by 5.3 units from days 1 to 3, whereas the scores of the group with partial or no withdrawal of TBZ treatment increased by 3.0 units (P = 0.0773). A post hoc analysis of the linear trend was positive for reemergent chorea (P = 0.0486). No serious adverse events were reported after abrupt withdrawal of TBZ treatment.
Conclusions: The trend for reemergence of chorea in patients with Huntington disease who were withdrawn from TBZ treatment is consistent with the findings from previous studies, thus showing the effectiveness of TBZ in reducing chorea.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WNF.0b013e3180ca77ea | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reversal of the motivational effects of tetrabenazine by NMDA receptor blockade.
Neuropharmacology
December 2024
- Department of Psychopharmacology, Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia. Electronic address:
Background: Apathy is a syndrome of decreased goal-directed activity, one of the main features of different brain disorders. Despite its high prevalence and life-threatening potential, there are currently very few options for its pharmacological treatment, which may be related to the lack of valid animal models.
Aims: The vesicular monoamine transporter 2 inhibitor tetrabenazine (TBZ) was used in this study to model apathy-related behavior in pathologies linked to a depletion of dopamine.
Neuroleptic malignant syndrome in Huntington disease.
Eur J Neurol
December 2024
Institute of Neurology, Catholic University of the Sacred Heart, Rome, Italy.
Article Synopsis
- A study evaluated the prevalence of neuroleptic malignant syndrome (NMS) in Huntington disease (HD) patients, finding that it is rarely reported despite the use of dopamine receptor blocking agents (DRBAs).
- Researchers reviewed patient data and case literature to assess NMS occurrences in a cohort of HD patients treated with DRBAs and tetrabenazine (TBZ).
- Results indicated only one diagnosed case of NMS among 5,108 patients, suggesting underreporting and highlighting critical risk factors like advanced disease stage and medication management issues.
Development and evaluation of nanostructured systems for cutaneous delivery of HS-releasing corticosteroids for skin inflammatory diseases.
Eur J Pharm Sci
December 2024
Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil. Electronic address:
Psoriasis is an immune-mediated chronic inflammatory disease that causes major psychosocial impact. Topical corticosteroids represent the standard pharmacological treatment for mild-to-moderate disease, but their local and systemic adverse effects reinforce the need for treatment innovations. Here we developed lamellar phase-based formulations for topical delivery of a hybrid dexamethasone and hydrogen sulfide (HS) donor molecule (Dexa-TBZ), aiming to potentiate the effects of the glucocorticoid with HS.
View Article and Find Full Text PDFWater-soluble AIE photosensitizer in short-wave infrared region for albumin-enhanced and self-reporting phototheranostics.
Biomaterials
March 2025
Department of Chemistry, and Department of Chemical and Biological Engineering, The Hong Kong Branch of Chinese National Engineering Research Center for Tissue Restoration and Reconstruction, Division of Life Science and State Key Laboratory of Molecular Neuroscience, The Hong Kong University of Science and Technology, Hong Kong, 999077, PR China; School of Science and Engineering, Shenzhen Institute of Aggregate Science and Technology, The Chinese University of Hong Kong, Shenzhen (CUHK-Shenzhen), Guangdong, 518172, PR China. Electronic address:
Organic photosensitizers (PSs) play important roles in phototheranostics, and contribute to the fast development of precision medicine. However, water-soluble and highly emissive organic PSs, especially those emitting in the short-wave infrared region (SWIR), are still challenging. Also, it's difficult to prepare self-reporting PSs for visualizing the treatment via stimulated emission depletion (STED) nanoscopy.
View Article and Find Full Text PDFTetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue.
Br J Pharmacol
December 2024
Laboratory of Molecular Pharmacology, HUN-REN Institute of Experimental Medicine, Budapest, Hungary.
Article Synopsis
- Tetrabenazine (TBZ) is a medicine that helps with moving too much, but we don't know everything about how it works in the brain.
- In experiments, TBZ was found to stop certain brain chemicals from being stored and released properly, which affects movement and behavior in mice.
- The study also showed that another drug, MDMA, could still make mice more active even when TBZ was affecting the brain's chemical release, helping us understand how these drugs work together.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!